Indian pharmas seek to protect their edge

Arguing that India will become a "contract manufacturing center" and "lose its edge," industry groups are seeking restrictions on foreign mergers and acquisitions. A panel of government officials recommended a foreign direct investment cap of 49% for brownfield projects while providing no cap for greenfield investments. But planning commission deputy chairman Montek Singh Ahluwalia said on Monday that he sees "no case for rollback" of FDI in the pharma sector. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.